Literature DB >> 15675610

SGS-742 Novartis.

Roger Bullock1.   

Abstract

SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15675610

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  5 in total

Review 1.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

Review 2.  Molecular aspects of age-related cognitive decline: the role of GABA signaling.

Authors:  Joseph A McQuail; Charles J Frazier; Jennifer L Bizon
Journal:  Trends Mol Med       Date:  2015-06-09       Impact factor: 11.951

3.  Novel, potent, and selective GABAC antagonists inhibit myopia development and facilitate learning and memory.

Authors:  Mary Chebib; Tina Hinton; Katrina L Schmid; Darren Brinkworth; Haohua Qian; Susana Matos; Hye-Lim Kim; Heba Abdel-Halim; Rohan J Kumar; Graham A R Johnston; Jane R Hanrahan
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

Review 4.  Drug development for Alzheimer's disease: where are we now and where are we headed?

Authors:  Marwan N Sabbagh
Journal:  Am J Geriatr Pharmacother       Date:  2009-06

Review 5.  GABAB Receptor Chemistry and Pharmacology: Agonists, Antagonists, and Allosteric Modulators.

Authors:  A Nieto; T Bailey; K Kaczanowska; P McDonald
Journal:  Curr Top Behav Neurosci       Date:  2022
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.